Feb 18, 2016 – BioGenerator Invests in New Immunotherapy Company, Unleash. Company will open operations in St. Louis.

Feb 18, 2016 – BioGenerator Invests in New Immunotherapy Company, Unleash. Company will open operations in St. Louis.

BioGenerator Invests in New Immunotherapy Company, Unleash
Company will open operations in St. Louis
ST. LOUIS – February 18, 2016 – BioGenerator, an evergreen investor that creates, grows and
invests in promising companies and entrepreneurs, has made an investment from its Concept
Fund into Unleash Immuno Oncolytics, a company focused on treatments of cancer.
Unleash is an immune-oncology company developing virus immunotherapy products to
treat cancer. The company was developed based on collaborations between Dr. David Curiel,
Director, Biologic Therapeutics Center at Washington University School of Medicine and Dr. Osvaldo Podhajcer, Director of the Argentinian Consortium of Genomic Technology and is licensing technology from Leloir Institute. As part of the funding, Unleash will set up headquarters in St. Louis and operate from CIC in the @4240 building.
BioGenerator is the investment arm of BioSTL, a nonprofit civic organization building
St. Louis’ innovation ecosystem and which in the last two years has added a focus of recruiting
international companies to the region. “Through our GlobalSTL initiative we are leveraging
St. Louis’ scientific and business strengths to attract cutting-edge technologies and talent that
enrich our region,” explained Donn Rubin, president and CEO of BioSTL. “Unleash’s decision to
locate in St. Louis is a testament to our world-class strengths in medicine and human health.”
“Unleash is based on technology from two leaders in the field of oncology and has
promising applications,” said Charlie Bolten, vice president of BioGenerator. “Immunotherapy is
a quickly evolving area of human health and BioGenerator is pleased to be one of the first
investors in a company at the cutting edge of research.”
Other investors in the round include Axia Ventures, a Latin American investment and
support organization. Unleash will use the initial investment to fund IND-enabling tasks including
cGMP manufacturing, toxicology and bio-distribution studies for its oncolytic immunotherapy
product.
¨We are pleased with BioGenerator’s role as lead investor in this round and establishing
Unleash in Saint Louis,” said Daniel Katzman, CEO of Unleash. “We are now eager to advance
Unleash’s virus immunotherapy products to the clinic.”
About BioGenerator
BioGenerator produces a sustained pipeline of successful bioscience companies and
entrepreneurs in St. Louis by creating, growing and investing in promising new enterprises.
BioGenerator is a nonprofit subsidiary of BioSTL, which advances St. Louis’ prosperity by
cultivating a thriving bioscience sector, building regional capacity to capitalize on St. Louis’ world
class medical and plant biosciences. Please visit www.BioGenerator.org for additional
information. Follow BioGenerator on LinkedIn linkedin.com/company/BioGenerator and Twitter
@BioGeneratorSTL.
###
Contact:
Colleen Ward
Office: 314.880.8873
Cell: 314.623.0450
cward@biostl.org